Labcorp Holdings (NYSE:LH) Introduces FDA-Approved Self-Collection Tests For HPV And STIs

Labcorp Holdings (NYSE:LH) saw its stock price increase by 1.49% over the last quarter, possibly driven by the announcement of its FDA-approved HPV self-collection solution and STI testing option aimed at improving women's health screening. These innovations might have boosted investor confidence despite the broader market's decline and uncertainties surrounding new tariffs impacting overall economic sentiment. The company's Q4 2024 financial results, showing improved net income and EPS, could have further bolstered investor sentiment, aligning its performance with the broader S&P 500's mixed recovery while distinguishing it from weaker areas like the airline sector.

Buy, Hold or Sell Labcorp Holdings? View our complete analysis and fair value estimate and you decide.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Labcorp Holdings (NYSE:LH) delivered a robust total return of 122.52% over the last five years. Key growth drivers include the acquisition of select assets from Invitae, which enhanced offerings in genetic testing and contributed to revenue growth in oncology. The launch of the Labcorp® Plasma Complete™ liquid biopsy test further reinforced its position in the genomics sector. Additionally, Labcorp actively pursued expansion with collaborations like the one with Xcell Biosciences, enhancing its capabilities in cell and gene therapy development.

The spin-off of Fortrea Holdings, Inc. marked a significant corporate restructuring, potentially impacting Labcorp's focus on core operations. Labcorp's commitment to shareholder value was evident through share repurchases totaling 72.19 million US$ in Q4 2024, while dividends also indicated solid cash flow management. Financially, Labcorp's impressive earnings growth contrasted the broader US Healthcare industry's one-year decline, highlighting its resilience and competitive advantage in a challenging market.

Assess Labcorp Holdings' future earnings estimates with our detailed growth reports.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com